C71T
CANCELLED SECTION 71
03/07/2026
Voltar para busca
Dado oficial do USPTO
MEDIGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
28/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
17/07/2018
Data de registro
17/12/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/07/2026
Última transação
28/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
27
Localização do titular
DE
Examinador
KIDWELL WALKER, JACLYN NOEMI
Unidade examinadora
M40
Localização atual
TMO LAW OFFICE 113
Titulares e representantes
Titulares
Medigene Immunotherapies GmbH
Representantes
Lisa C. Pavento Meunier Carlin & Curfman LLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations namelycellular preparationsT-cell preparations and DC (dendritic cell) preparations for the treatment of cancer and use in immunotherapy; medical compositions for the treatment of hematological and solid tumorstumor precursors; test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of antibodiestest kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of soluble T-cell receptorstest kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of genetically modified cells and test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting of a composition of antibodiessoluble T-cell receptors and genetically modified cells; diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable mediumin particular produced using molecular biologicalbiotechnological and genetic methods
Classe 42
Services in molecular biologyresearch and development in the field of medical and veterinary diagnosis and treatment using molecular biologicalbiotechnological and genetic methodsin the field of screening for compounds with pharmaceutical properties; development of test methods and test kits in the field of hematological and solid tumor immunology; biological cell analyses; development of individualized medicinedevelopment of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific and therapeutic purposes; development of adoptive T cell therapy; development of DC vaccines; development of cellular tumour therapy; development of tumour markers; development of diagnostic and therapeutic antibodies; cell analyses; development of individualised medicinedevelopment of treatment plans and therapy adapted for individual patients
Classe 44
Medical and veterinary medical servicesin particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
17/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/08/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/08/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/08/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/08/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/08/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/05/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/03/2020
FIMP
FINAL DISPOSITION PROCESSED
28/03/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/03/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
17/12/2019
GPNX
NOTIFICATION PROCESSED BY IB
05/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/10/2019
PUBO
PUBLISHED FOR OPPOSITION
01/10/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/09/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/09/2019
ALIE
ASSIGNED TO LIE
29/08/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/08/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
22/08/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/08/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
22/08/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/08/2019
RFNT
REFUSAL PROCESSED BY IB
02/03/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/02/2019
RFRR
REFUSAL PROCESSED BY MPU
14/02/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/02/2019
CNRT
NON-FINAL ACTION WRITTEN
05/02/2019
MAFR
APPLICATION FILING RECEIPT MAILED
01/02/2019
DOCK
ASSIGNED TO EXAMINER
28/01/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/01/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/01/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEDIGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.